Table 5.
Bivariate and multivariate analysis of baseline biomarker levels in patients with acute lung injury
Biomarker, Day 0 | n | Median Value, Trauma | Median Value, Nontrauma | Unadjusted p Value | Multivariable p Value |
---|---|---|---|---|---|
ICAM-1, ng/mL | 1307 | 410 (272–738) | 765 (480–1223) | <.001 | <.001 |
SP-D, ng/mL | 1075 | 58 (37–94) | 95 (45–211) | <.001 | .001 |
Protein C, % of control | 1308 | 58 (45–78) | 53 (35–84) | .07 | .14 |
vWF, % of control | 1088 | 226 (142–331) | 355 (215–551) | <.001 | <.001 |
PAI-1, ng/mL | 1304 | 56 (36–104) | 70 (37–157) | .045 | .95 |
IL-6, pg/mL | 1302 | 300 (128–674) | 259 (100–850) | .44 | .047 |
IL-8, pg/mL | 1309 | 21 (20–59) | 44 (20–103) | .002 | .30 |
sTNFr-1, pg/mL | 1091 | 2535 (1945–3332) | 3748 (2340–7661) | <.001 | .004 |
ICAM, intercellular adhesion molecule; SP-D, surfactant protein D; vWF, von Willebrand factor antigen; PAI, plasminogen activator inhibitor; IL, interleukin; sTNFr, soluble tumor necrosis factor receptor.
All biomarker values represent median (interquartile range) with bivariate comparison using Mann-Whitney U test. Multivariable linear model (using natural log-transformed biomarker levels) controls for age, gender, ethnicity, presence of significant comorbidities (acquired immunodeficiency syndrome, immunosuppression, diabetes, and end-stage renal disease), severity of injury, and Pao2/Fio2 ratio.